Health X Platform quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	447	298	+49.7%
EBITDA	−8.4	6.1	—
EBITDA margin	−1.9%	2.0%	−3.9 pts
Profit before tax	2.0	30.2	−93.5%
Net profit	2.0	26.6	−92.5%
EPS	₹0.80	₹7.52	−89.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	447	374	346	301	298	286	281	274	270	307	374	358	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	12.8	13.8	13.6	5.5	25.4	21.6	−11.8	22.3	27.7	18.5	20.1	9.7
	460	388	359	307	324	307	269	296	298	325	395	368
	0.2	0.1	0.2	0.3	0.3	0.3	0.4	0.5	0.6	0.4	0.3	0.7
	448	374	326	289	260	269	268	235	245	251	319	325
	−42.1	−23.1	−10.8	−4.6	−2.9	−3.7	−4.9	11.1	−2.7	30.2	15.9	−5.6
	27.7	25.0	21.7	19.9	17.3	16.3	11.2	11.6	10.6	11.9	12.3	12.9
	0.6	0.5	0.2	0.0	0.1	0.0	0.1	0.1	0.1	0.3	0.2	0.2
	1.9	1.9	2.2	1.3	1.2	1.3	1.4	1.5	1.6	2.5	2.3	2.2
	21.4	23.3	19.2	19.1	17.4	29.4	30.7	20.3	19.4	23.7	23.0	21.9
	458	401	358	325	294	312	306	280	274	320	374	358
	−8.4	−25.2	−10.4	−22.6	6.1	−25.2	−23.7	−4.7	−2.4	−10.6	3.4	3.4
	−10.3	−27.1	−12.5	−23.9	4.9	−26.5	−25.1	−6.2	−4.0	−13.2	1.1	1.2
Profit
	2.0	−13.9	0.9	−18.5	30.2	−4.9	−37.0	16.0	23.6	5.0	21.0	10.6
	0.0	−1.0	0.0	−0.2	0.0	0.3	−2.2	−190	1.0	0.0	0.0	0.0
	2.0	−14.8	0.9	−18.6	30.2	−4.6	−39.2	−174	24.6	5.0	21.0	10.6
	0.5	0.2	0.1	0.2	0.3	−11.4	15.2	0.2	0.9	−22.6	1.1	4.1
	−0.5	−2.0	0.4	−3.4	3.3	−10.8	−14.4	−23.1	−26.2	−6.6	−0.3	−6.6
	−0.0	−1.9	0.6	−3.2	3.6	−22.2	0.8	−22.9	−25.3	−29.2	0.8	−2.5
	0.0	0.0	0.0	0.0	0.0	0.0	2.2	−4.0	−9.0	−12.7	−23.4	−25.3
	2.0	−13.0	0.4	−15.4	26.6	17.6	−37.8	−155	41.0	21.6	−3.2	−12.2
	2.0	−13.0	0.4	−15.4	26.6	17.6	−40.0	−151	50.0	34.2	20.2	13.1
	−0.6	1.5	0.1	0.3	0.2	−0.7	0.1	−0.1	0.3	0.2	−0.0	0.3
	1.4	−11.5	0.5	−15.1	26.8	16.9	−37.7	−155	41.2	21.7	−3.3	−11.9
	2.5	−11.2	1.1	−12.7	23.9	13.7	−26.9	−109	31.2	16.4	−0.7	−8.1
	−0.6	−1.8	−0.8	−2.7	2.7	3.9	−10.9	−45.4	9.8	5.1	−2.5	−4.1
Per share
	₹0.80	−₹3.51	₹0.35	−₹3.99	₹7.52	₹4.30	−₹8.47	−₹34.40	₹9.79	₹5.17	−₹0.23	−₹2.55
	₹0.80	−₹3.51	₹0.35	−₹3.99	₹7.52	₹4.30	−₹8.47	−₹34.40	₹9.79	₹5.17	−₹0.23	−₹2.55
Revenue detail — as filed
	440	379	340	306	278	281	279	263	262	302	365	353
	0.7	−1.0	1.3	1.5	0.7	0.7	0.7	0.8	0.9	0.8	1.8	2.0
	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.1
	6.3	−4.6	4.2	−7.7	19.7	3.7	1.2	9.4	7.1	3.9	7.1	−2.8
	0.0	0.0	—	—	—	—	—	—	—	—	—	—
Other comprehensive income — detail
	−0.6	1.5	0.1	0.3	0.2	−0.7	0.1	−0.1	0.3	0.2	−0.0	0.3
	−1.2	1.0	0.2	0.5	0.2	−1.0	0.1	−0.1	0.3	0.3	−0.0	0.3
	−0.3	0.2	0.0	0.2	−0.0	−0.2	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	−0.0	0.1	−0.0	−0.0
	0.4	0.9	—	—	—	—	—	—	—	—	—	—
	0.1	0.2	—	—	0.0	—	—	—	—	—	—	—
	2.1	−10.0	1.2	−12.5	24.1	13.1	−26.9	−109	31.3	16.6	−0.8	−7.9
	−0.7	−1.5	−0.7	−2.7	2.8	3.7	−10.8	−45.4	9.9	5.2	−2.5	−4.0
Per share — as-filed variants
	₹0.80	−₹3.51	₹0.35	−₹3.99	₹7.52	₹4.30	−₹8.47	−₹34.40	₹9.79	₹5.17	−₹0.23	−₹2.55
	₹0.80	−₹3.51	₹0.35	−₹3.99	₹7.52	₹4.30	−₹8.47	−₹34.40	₹9.79	₹5.17	−₹0.23	−₹2.55
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	40.8	23.2	30.5	16.3	40.8	20.5	18.3	27.2	27.6	25.0	38.8	38.2
	9.1%	6.2%	8.8%	5.4%	13.7%	7.2%	6.5%	9.9%	10.2%	8.2%	10.4%	10.7%
Adjusted (ex-exceptional items) — derived
	2.0	−13.9	0.9	−18.5	30.2	−4.9	−37.0	16.0	23.6	5.0	21.0	10.6
	0.0	−1.0	0.0	−0.2	0.0	0.3	−2.2	−190	1.0	0.0	0.0	0.0
	2.0	−12.1	0.4	−15.3	26.6	17.5	−35.6	9.9	40.0	21.6	−3.2	−12.2
	₹0.80	−₹3.28	₹0.35	−₹3.95	₹7.52	₹4.27	−₹7.97	₹2.20	₹9.55	₹5.17	−₹0.23	−₹2.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HEALTHX₹279.20

Health X Platform Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSURAKSHA KRSNAA NEPHROPLUS 3BBLACKBIOMcap ₹888 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	358.5	374.5	306.7	270.3	273.5	281.3	285.8	298.4	301.3	345.7	373.8	446.8
Other Income	9.7	20.1	18.5	27.7	22.3	-11.8	21.6	25.4	5.5	13.6	13.8	12.8
Total Income	368.2	394.6	325.1	298.0	295.8	269.5	307.5	323.8	306.8	359.4	387.5	459.7
Expenses
+ Cost of Materials Consumed	0.7	0.3	0.4	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.1	0.2
+ Purchases of Stock-in-Trade	325.2	319.5	251.0	244.8	234.8	267.6	268.7	260.2	289.3	325.8	373.6	448.0
+ Changes in Inventories	-5.6	15.9	30.2	-2.7	11.1	-4.9	-3.7	-2.9	-4.6	-10.8	-23.1	-42.1
+ Employee Benefit Expense	12.9	12.3	11.9	10.6	11.6	11.2	16.3	17.3	19.9	21.7	25.0	27.7
+ Finance Costs	0.2	0.2	0.3	0.1	0.1	0.1	0.0	0.1	0.0	0.2	0.5	0.6
+ Depreciation & Amortisation	2.2	2.3	2.5	1.6	1.5	1.4	1.3	1.2	1.3	2.2	1.9	1.9
+ Other Expenses	21.9	23.0	23.7	19.4	20.3	30.7	29.4	17.4	19.1	19.2	23.3	21.4
Total Expenses	357.6	373.6	320.1	274.4	279.8	306.5	312.4	293.6	325.3	358.4	401.4	457.7
EBITDA	3.4	3.4	-10.6	-2.4	-4.7	-23.7	-25.2	6.1	-22.6	-10.4	-25.2	-8.4
EBIT	1.2	1.1	-13.2	-4.0	-6.2	-25.1	-26.5	4.9	-23.9	-12.5	-27.1	-10.3
Profit
PBT before Exceptional Items	10.6	21.0	5.0	23.6	16.0	-37.0	-4.9	30.2	-18.5	0.9	-13.9	2.0
+ Exceptional Items	0.0	0.0	0.0	1.0	-189.7	-2.2	0.3	0.0	-0.2	0.0	-1.0	0.0
Pretax Income	10.6	21.0	5.0	24.6	-173.6	-39.2	-4.6	30.2	-18.6	0.9	-14.8	2.0
+ Current Tax	4.1	1.1	-22.6	0.9	0.2	15.2	-11.4	0.3	0.2	0.1	0.2	0.5
+ Deferred Tax	-6.6	-0.3	-6.6	-26.2	-23.1	-14.4	-10.8	3.3	-3.4	0.4	-2.0	-0.5
Tax Expense	-2.5	0.8	-29.2	-25.3	-22.9	0.8	-22.2	3.6	-3.2	0.6	-1.9	-0.0
+ Share of Associates & JVs	-25.3	-23.4	-12.7	-9.0	-4.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	-12.2	-3.2	21.6	41.0	-154.8	-37.8	17.6	26.6	-15.4	0.4	-13.0	2.0
+ Net Income — Continuing Ops	13.1	20.2	34.2	50.0	-150.8	-40.0	17.6	26.6	-15.4	0.4	-13.0	2.0
+ Other Comprehensive Income	0.3	-0.0	0.2	0.3	-0.1	0.1	-0.7	0.2	0.3	0.1	1.5	-0.6
Total Comprehensive Income	-11.9	-3.3	21.7	41.2	-154.9	-37.7	16.9	26.8	-15.1	0.5	-11.5	1.4
Net Income to Common	-8.1	-0.7	16.4	31.2	-109.4	-26.9	13.7	23.9	-12.7	1.1	-11.2	2.5
Minority Interest	-4.1	-2.5	5.1	9.8	-45.4	-10.9	3.9	2.7	-2.7	-0.8	-1.8	-0.6
Per Share
Basic EPS	-2.55	-0.23	5.17	9.79	-34.40	-8.47	4.30	7.52	-3.99	0.35	-3.51	0.80
Diluted EPS	-2.55	-0.23	5.17	9.79	-34.40	-8.47	4.30	7.52	-3.99	0.35	-3.51	0.80
Revenue Detail — as filed
+ Sale of Products	353.5	365.0	301.6	262.0	262.7	279.1	281.2	277.8	306.5	340.0	379.1	439.6
+ Sale of Services	2.0	1.8	0.8	0.9	0.8	0.7	0.7	0.7	1.5	1.3	-1.0	0.7
+ Dividend Income	0.1	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.9	0.0	0.0	0.0
+ Net Gain on Fair Value Changes	-2.8	7.1	3.9	7.1	9.4	1.2	3.7	19.7	-7.7	4.2	-4.6	6.3
+ Other Operating Revenue	—	—	—	—	—	—	—	—	—	—	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.3	-0.0	0.2	0.3	-0.1	0.1	-0.7	0.2	0.3	0.1	1.5	-0.6
+ Items NOT to be Reclassified to P&L	0.3	-0.0	0.3	0.3	-0.1	0.1	-1.0	0.2	0.5	0.2	1.0	-1.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.2	-0.0	0.2	0.0	0.2	-0.3
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.0	0.1	-0.0	0.0	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	—	—	—	0.9	0.4
+ Tax on Items to be Reclassified	—	—	—	—	—	—	—	0.0	—	—	0.2	0.1
Comprehensive Income — Owners of Parent	-7.9	-0.8	16.6	31.3	-109.5	-26.9	13.1	24.1	-12.5	1.2	-10.0	2.1
Comprehensive Income — Non-controlling Interests	-4.0	-2.5	5.2	9.9	-45.4	-10.8	3.7	2.8	-2.7	-0.7	-1.5	-0.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	-2.55	-0.23	5.17	9.79	-34.40	-8.47	4.30	7.52	-3.99	0.35	-3.51	0.80
Diluted EPS — Continuing Operations	-2.55	-0.23	5.17	9.79	-34.40	-8.47	4.30	7.52	-3.99	0.35	-3.51	0.80
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	38.2	38.8	25.0	27.6	27.2	18.3	20.5	40.8	16.3	30.5	23.2	40.8
Gross Margin %	10.66	10.35	8.16	10.20	9.93	6.49	7.19	13.68	5.42	8.83	6.20	9.12
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	10.6	21.0	5.0	23.6	16.0	-37.0	-4.9	30.2	-18.5	0.9	-13.9	2.0
− Exceptional Items (reconciliation)	0.0	0.0	0.0	1.0	-189.7	-2.2	0.3	0.0	-0.2	0.0	-1.0	0.0
Net Income Adj (tax-effected)	-12.2	-3.2	21.6	40.0	9.9	-35.6	17.5	26.6	-15.3	0.4	-12.1	2.0
EPS Adj	-2.55	-0.23	5.17	9.55	2.20	-7.97	4.27	7.52	-3.95	0.35	-3.28	0.80
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Interest Earned	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Paid Up Equity Capital	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Health X Platform quarterly results

Health X Platform (NSE: HEALTHX) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹2.5 crore, down 89.4% from ₹23.9 crore in Q1 FY26 and against a loss of ₹11.2 crore in Q4 FY26. Revenue from operations was ₹447 crore, up 49.7% year on year and up 19.5% from the previous quarter.

Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 7 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹2.5 Cr−89.4% vs Q1 FY26loss ₹11.2 Cr in Q4 FY26
Q1 FY27 revenue: ₹447 Cr+49.7% vs Q1 FY26+19.5% vs Q4 FY26
Q1 FY27 operating margin: −2.3%−3.9 pts vs Q1 FY26+5.0 pts vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹12.7 CrRevenue ₹301 Cr
Q1 FY27 EPS (basic): ₹0.80

Questions

When will Health X Platform announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 13 November 2025.

What were Health X Platform's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹2.5 crore, down 89.4% from ₹23.9 crore in Q1 FY26 and against a loss of ₹11.2 crore in Q4 FY26. Revenue from operations was ₹447 crore, up 49.7% year on year and up 19.5% from the previous quarter.

What was Health X Platform's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1.2 crore in FY26 (April 2025–March 2026), against a loss of ₹91.2 crore in FY25. It was a profit of ₹8.9 crore in FY24 and a loss of ₹72.2 crore in FY23.

What will Health X Platform's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss attributable to shareholders was ₹12.7 crore and revenue from operations ₹301 crore. The latest quarter, Q1 FY27, had a net profit of ₹2.5 crore and revenue of ₹447 crore.

How has Health X Platform's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: a loss of ₹12.7 crore in Q2 FY26, a profit of ₹1.1 crore in Q3 FY26, a loss of ₹11.2 crore in Q4 FY26 and a profit of ₹2.5 crore in Q1 FY27. That is a combined loss of ₹20.2 crore over the four quarters. Revenue from operations: ₹301 crore, ₹346 crore, ₹374 crore and ₹447 crore.

What was Health X Platform's revenue in FY26?

Revenue from operations was ₹1,319 crore in FY26 (April 2025–March 2026), up 18.8% from ₹1,111 crore in FY25. It was ₹1,376 crore in FY24 and ₹1,040 crore in FY23: up 26.9% over three years, 8.3% a year on average.

Where do these Health X Platform figures come from?

From Health X Platform's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.